Camrelizumab
艾瑞卡
A Chinese-developed PD-1 immunotherapy (Hengrui).
At a glance
China price
Verified pricing is not currently available.
NRDL (national insurance)
In NRDL.
Regulatory status
NMPA approved (2019); NRDL
What this meansSupported by a credible secondary source but not yet independently confirmed against a primary source.
SourceNo independent source on file.
NotesApproval status from public regulatory reporting.
What it treats
Hodgkin lymphoma, liver cancer, NSCLC, esophageal and nasopharyngeal cancers.
(himd.com)/
Sources & verification
No independent source is currently on file. We have not independently verified this information.
Reader discussion
Public comments about Camrelizumab. Discussion is not medical advice, and a comment is not an endorsement or a verified fact. Open the full forum.